• UCLA Health
  • myUCLAhealth
  • School of Medicine
UCLA Health

UCLA Health
  • About Us
    • What is UCLA Health?
    • Contact Us
    • Your Feedback
    • Accountable Care Organization
    • Awards & Achievements
    • Careers
    • Careers for Physicians
    • Departments - Administrative
    • Departments - Clinical
    • Giving to UCLA Health
    • Health Equity, Diversity & Inclusion
    • In the Community
    • Industry Relations
    • Innovation
    • Leadership
    • News Releases
    • Price Transparency
    • Social Media
    • #TeamLA
    • 340B Program
    Vital SignsLinked Graphic: Subscribe to Health Newsletters
    • Contact
    • Your Feedback
    • Accountable Care Organization
    • Awards and Achievements
    • Careers
    • Careers for Physicians
    • Departments - Administrative
    • Departments - Clinical
    • Giving to UCLA Health
    • Health Equity, Diversity and Inclusion
    • Industry Relations
    • Innovation
    • In the Community
    • 340B Program
    • Leadership
    • News Releases
    • Price Transparency
    • Social Media
    • TeamLA
    • Subscribe to UCLA Health Newsletters
  • Conditions & Treatment
    • Health Library
    • Tests & Procedures
    • Drug Interaction Checker
    • Brain & Nervous System
    • Cancer
    • Children's Health
    • Heart Disease
    • Nutrition & Wellness
    • Pregnancy & Newborns
    • Orthopedics
    • Women's Health
    • Video Library
    • Cancer
    • Cardiovascular
    • Chiropractic
    • Cosmetic Surgery
    • Ear, Nose and Throat
    • Gastrointestinal
    • General Healthcare
    • Neurological
    • Obstetrics/Gynecology
    • See all videos...
    Symptom Checker
    • Video Library
  • Locations

    Hospitals

    • Ronald Reagan UCLA Medical Center
    • UCLA Santa Monica Medical Center
    • UCLA Mattel Children's Hospital
    • Resnick Neuropsychiatric Hospital
    • Institutes and Centers
    • Take a Virtual Tour

    Medical Offices/Clinics

    • Primary Care
    • Specialty Care
    • Immediate Care
    • Emergency Care
    • Outpatient Surgery Centers
    • Community Cancer Care
    • Pediatric Locations
    • Imaging/Radiology
    • Clinical Labs
    • Pharmacies

    Interactive Map

    interactive map

    • Interactive Map
    • UCLA Medical Plazas
    • Locations Coming Soon
    • UCLA Hospitals
    • Take a Virtual Tour
    • Primary Care Practices
    • Specialty Care Practices
    • Immediate Care
    • Emergency Care
    • Pediatric Locations
    • Outpatient Surgery Centers
    • Clinical Labs
    • Pharmacies
    • Other Locations
    • Interactive Map
    • Coming Soon!
  • Medical Services
  • For Patients & Visitors
    • Directions & Parking
    • Appointments
    • Video Visits
    • Medical Chaperones
    • Admissions
    • Preparing For Surgery
    • Patient Services
    • Security & Parking Services
    • Office of the Patient Experience
    • For International Patients
    • Lodging & Nearby Services
    • Around Westwood
    • Gift Shops & Flowers
    • Patient Greeting Cards
    • Coronavirus Resources
    • Log in to myUCLAhealth
    • Billing and Insurance
    • Medical Records
    • Price Transparency
    • Health Encyclopedia
    • Interactive Patient Education Videos (Emmi)
    • FAQs
    • Calendar of Events
    • Secure Email Messages
    • Health Resources
    • Multimedia
    • Download our Apps
    • Doctor on video visit
    • Open Enrollment
    • Visit our Connect Blog
    • Send a Care Compliment
    • Read Health Publications
    • Vital Signs Newsletters
    • Join a Patient and Family Advisory Council
    • Share your Feedback
    • Contact Us
    • Appointments: Call, Click, Come in
    • Video Visits - Telemedicine
    • Medical Chaperones
    • Admissions Information
    • Advance Directive
    • Directions & Parking
    • Patient Services
    • Medical Records
    • myUCLAhealth
    • Smoke-Free
    • Publications
    • Multimedia
    • Health Resources
    • Around Westwood
    • Lodging
    • Preparing For Surgery
    • Patient-focused Technology Council
    • Health Forms
    • End of Life Option Act: Resources & Materials
    • Frequently Asked Questions
    • Secure Email Messages
    • Gift Shops
    • Patient Greeting Cards
  • For Healthcare Professionals
    • Referring a Patient
    • Continuing Medical Education
    • Ethics Center
    • UCLA HealthLink
    • Physician to Physician Access Line (P2P)
    • David Geffen School of Medicine at UCLA
    • Clinical Informatics Fellowship
    • Academic Positions
    • Physician Careers
    • UCLA School of Dentistry
    • UCLA School of Nursing
    • Department of Nursing

    Physician Publications

    • Physicians Update
    • Clinical Updates
    • U Magazine
    • Physician to Physician Access Line (P2P)
    • Physician Careers
    • Clinical Informatics Fellowship
    • Flu Resources for Healthcare Professionals
    • Publications
  • Clinical Research
    • All Clinical Trials
    • COVID-19 Clinical Research
  • Find a Provider
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

News Releases

  1. Home
  2. About Us
  3. News Releases

News Releases

Health and Behavior

Drug combination therapy for estrogen-receptor–positive breast cancer passes critical step for worldwide approval

UCLA study showed positive results without the side effects of traditional chemotherapy

11/16/2016

Building on earlier clinical trials, UCLA researchers have confirmed that the “breakthrough” drug palbociclib when used in combination with the traditional hormonal therapy letrozole delays progression of advanced breast cancer significantly and without the harsh side effects seen in some women prescribed letrozole alone.

The study, published online today in the New England Journal of Medicine, is the phase 3 study following phase 1 and phase 2 clinical trials that led to U.S. Food and Drug Administration approval of palbociclib in early 2015. Palbociclib was also approved in Europe for the first time earlier in November based on these results. In 2013, after women in a clinical study led by UCLA researchers showed a dramatic improvement, the FDA granted palbociclib “breakthrough therapy” status, allowing it to be fast-tracked for approval.

The drug combination is the first and only treatment for women with estrogen-receptor–positive breast cancer to show such significant results in a randomized phase 3 trial. Dr. Richard Finn and Dr. Dennis Slamon of the UCLA Jonsson Comprehensive Cancer Center led the laboratory studies and previous trials and are co-authors of the study.

“These results are a truly meaningful advancement for women in this patient population,” said Finn, who is also an associate professor of medicine in the David Geffen School of Medicine at UCLA. “The results of the phase 3 study will support the full approval of palbociclib in the United States and around the world.”

Palbociclib (marketed as Ibrance by Pfizer) is known as the first new drug that in combination with hormonal therapy has proven to be very effective in post-menopausal women with estrogen receptor-positive breast cancer. Estrogen-receptor–positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer subgroup represents the largest proportion of breast cancer cases and is traditionally treated with therapies, like tamoxifen or letrozole, that target the hormone receptor pathway. Palbociclib, which was developed by Pfizer, prevents cells from dividing by targeting a key family of proteins (CDK4/6) responsible for cell growth.

Led by Finn and Slamon, an international team of investigators from 17 countries analyzed 666 women with advanced ER+/HER2- breast cancer. The people were treated with a combination of palbociclib and letrozole, and had not received prior systemic therapy for their cancer. The results of the new study confirmed the previous findings of the multi-year phase 1 and phase 2 trials, which showed a significant increase in progression-free survival, meaning without the cancer worsening, compared to letrozole alone.

The phase 2 trial also demonstrated that survival without side effects nearly doubled — 20.2 months for women who received palbociclib plus letrozole compared to 10.2 months in patients who received letrozole alone — representing a 42 percent reduction in the risk of disease progression. The new phase 3 trial further confirmed these findings.

“The results from both studies are really remarkable for the degree of benefit they provide in slowing the growth of estrogen-receptor positive breast cancer,” said Slamon, director of the Revlon/UCLA Women’s Cancer Research Program and director of clinical and translational research at the Jonsson Cancer Center. “The drug combination is very well tolerated and without the side effects of traditional chemotherapy, such as infections, nausea and significant hair loss.”

Palbociclib is the first CDK 4/6 treatment to be approved for cancer treatment and provides proof of concept that targeting this pathway is important for the treatment of women with ER+ breast cancer. The researchers said the phase 3 findings will open the door to further studies in breast cancer and other diseases. Besides leading the clinical development, the initial scientific observation that drove the development of palbociclib and other CDK 4/6 inhibitors in breast cancer came out of work from the UCLA Translational Oncology Research Laboratories under the direction of Finn and Slamon.

Funding for the phase 3 clinical trial was provided by Pfizer. Finn is a consultant for Pfizer and Slamon has stock in the company.



Media Contact
Reggie Kumar
310-206-2805
reggiekumar@mednet.ucla.edu



Latest News

Health and Behavior
UCLA shares COVID-19 vaccine information with faculty and staff
01/15/2021
Members of the COVID-19 Response and Recovery Task Force updated faculty and staff on the progress of UCLA Health's vaccination program and to take questions.

Health and Behavior
In lab study, nanoparticle shows promising results for treating severe allergies
01/14/2021
A UCLA research team developed a possible way to impart long-term relief by inducing an active state of immune tolerance.

Health and Behavior
Cancer researchers awarded grant to study genomic alterations in prostate cancer
01/12/2021
Paul Boutros, PhD, Robert Reiter, MD, and Huihui Ye, MD, MS, of the UCLA Jonsson Comprehensive Cancer Center have received the 2020 Prostate Cancer Foundation Special Challenge Award to help improve the understanding of prostate cancer biology and identify new ways to help prevent, diagnose, prognose and treat lethal prostate cancer.

Health and Behavior
UCLA scientists develop method to more efficiently isolate and identify rare T cells
01/11/2021
Scientists from the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have developed a technique that will enable researchers to more efficiently isolate and identify rare T cells that are capable of targeting viruses, cancer and other diseases.

Health and Behavior
MRI frequently underestimates tumor size in prostate cancer
01/07/2021
Research brief: Improving imaging processes will lead to more successful treatments and help reduce morbidity in men with the disease.

Facebook Twitter Instagram Youtube LinkedInWeibo
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap

Sign in to myUCLAhealth

Learn more about myUCLAhealth